We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novo Nordisk is exploring beyond its well-paved diabetes track, acquiring its first investigational neurological compound, PRX004, from Prothena in a deal potentially worth up to $1.2 billion. Read More
The FDA approved Austedo in 2017 for treatment of chorea — a condition associated with Huntington’s disease that involves involuntary jerky movements. Read More
AstraZeneca’s planned acquisition of Alexion Pharmaceuticals, a prominent developer of drugs for rare diseases, has received a green light from the European Commission. Read More
Emergent BioSolutions was hit with a potential class-action lawsuit on Wednesday, alleging the company made false and misleading statements regarding its manufacturing capabilities and quality control processes at its Bayview facility in Baltimore, Md. Read More
GlaxoSmithKline (GSK) and Alector have forged a $2.2 billion pact to develop monoclonal antibodies for treating Parkinson’s and Alzheimer’s diseases, among other neurological conditions. Read More
Biogen said it plans to price the monthly infusion at $4,312 or $56,000 annually, a price that many critics say will quickly bankrupt Medicare. Read More